Beyondspring Pharmaceuticals, Inc.

Beyondspring Inc.

Yolare Pharmaceuticals, LLC

Hywe Pharmaceuticals, Inc.

Staidson Biopharmaceuticals Co., Ltd.

Lan Huang

Ramon Mohanlal

George Kenneth Lloyd

Aniruddh Singh

Santosh Ambadas Khedkar

Michel O Steinmetz

Yong Cang

Renato (Rene) Jose

James R Tonra

Xing Li

Disclosed herein are plinabulin and the use for reducing neutropenia. Some embodiments relate to reducing the docetaxel induced neutropenia using plinabulin.

Method of stimulating neutrophil survival and reducing neutropenia

Disclosed herein are compounds that can bind to tubulin and activate GEF-H1. Methods of using these compounds for treating cancer are also disclosed.

Tubulin binding compounds and therapeutic use thereof

Disclosed herein are methods of reducing neutropenia that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Composition and method for reducing neutropenia

Disclosed herein are methods of treating, preventing or ameliorating a disease or condition associated with cancer or a tumor. In some embodiments, the method includes administering a compound of Formula (I) to a subject in need thereof wherein the cancer or the tumor is or becomes resistant to one or more immune checkpoint inhibitors.

Therapeutic compositions and methods for treating checkpoint inhibitor-resistant tumors using plinabulin-based combination therapies

Disclosed herein are plinabulin polymorphs, compositions, their use and preparation as therapeutic agents. In particular, some embodiments relate to plinabulin monohydrate in a crystalline form.

Plinabulin compositions

Disclosed herein are methods of treating a cancer characterized by expressing a mutant form of a RAS protein. Some embodiments relate to treatment of cancer by administering Plinabulin to a subject in need thereof.

Method of treating cancer associated with a RAS mutation

Disclosed herein are compositions including a compound of formula (I) for treating cancer. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and one or more immune checkpoint inhibitor to a subject in need thereof. Some embodiments relate to methods of treating cancer by co-administering a compound of formula (I) and plinabulin to a subject in need thereof. Some embodiments relate to methods of providing co-stimulation of T-cell activation against cancer by co-administering a compound of formula (I), one or more immune checkpoint inhibitor.

Compositions containing tucaresol or its analogs

Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Growing community of inventors

Bronx, NY, United States of America

Lan Huang